Earnings Report /

Beximco Pharmaceuticals: Q1 FY22 – Earnings increased by c36% YoY driven by c22% sales growth

  • BXPHARMA reported BDT 3.28 EPS (NPAT BDT 1,465mn) in Q1 FY22, implying c36% YoY growth

  • Revenue increased by 22% YoY because of higher sales of drugs to treat COVID symptoms and normalized doctor consultancy.

  • BXPHARMA has completed the acquisition of Sanofi Bangladesh Limited (SBL), effective from October 1, 2021

Shopnil Paul
Shopnil Paul

Research Associate

Tanay Kumar Roy
Tanay Kumar Roy

Research Analyst

IDLC Securities
14 November 2021
Published by